comparemela.com

Latest Breaking News On - Genentech columvi - Page 1 : comparemela.com

From Axatilimab to Zanubrutinib: Treatment Updates Abound

Presentations detail clinical trial results and focus on drugs in the pipeline.

United statesSan diegoMdss mpnsFrellickm zanubrutinibEhlersj tuspetinibSmithj valemetostatRoche columviSyndax incyteTallenta nivolumabEhlersj fedratinibRddady ibrutinibGenentech columviTuspetinib aptose biosciencesIngrami meninRddady daratumumabTallenta isatuximab

Fixed-Duration Glofitamab Approved in Europe for Relapsed/Refractory DLBCL

The European Commission has granted conditional marketing authorization to glofitamab for fixed-duration administration in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic treatment.

Michael dickinsonGenentech columviEuropean commissionPeter maccallum cancer centreRoyal melbourne hospital

BioBlast f/e 16 Jun 23

BioBlast f/e 16 Jun 23
lexology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lexology.com Daily Mail and Mail on Sunday newspapers.

West virginiaUnited statesUnited kingdomSouth koreaNew zealandGenentech columviSamsung bioepisRegeneron eyleaGenentech ocrevusAmgen bekemvAbbvie humiraGenentech actemraGenentech herceptinJanssen remicadeAlexion solirisMark cuban

Columvi Approved for Relapsed or Refractory DLBCL or LBCL

Columvi (glofitamab) has accelerated approval for relapsed/refractory DLBCL not otherwise specified or LBCL arising from follicular lymphoma.

Genentech columviDrug administrationAccessed june

FDA approves off-the-shelf bispecific antibody cancer therapy

The US Food and Drug Administration (FDA) has approved the first bispecific antibody with a fixed-duration treatment in DLBCL.

Genentech columviLevi garrawayDrug administrationHead of global product developmentChief medical officerGlobal product developmentNew england journal

vimarsana © 2020. All Rights Reserved.